Is PLYX or LSTA more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Lisata Therapeutics N/A -103.54% -83.08%

Is LSTA or CRDL more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Cardiol Therapeutics N/A -229.43% -165.60%

Is PMN or LSTA more profitable?

Lisata Therapeutics' return on equity of -103.54% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Lisata Therapeutics N/A -103.54% -83.08%

Do analysts prefer CUE or LSTA?

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 358.72%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ENGN or LSTA more profitable?

enGene's return on equity of -56.06% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Lisata Therapeutics N/A -103.54% -83.08%

Lisata Therapeutics (LSTA) Competitors

$3.27 +0.04 (+1.24%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$3.28 +0.02 (+0.46%)

As of 07/10/2026 06:10 PM Eastern

Compare

LSTA vs. PLYX, CRDL, PMN, CUE, and ENGN

Should you buy Lisata Therapeutics stock or one of its competitors? MarketBeat compares Lisata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lisata Therapeutics include Polaryx Therapeutics (PLYX), Cardiol Therapeutics (CRDL), Promis Neurosciences (PMN), Cue Biopharma (CUE), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

In the previous week, Polaryx Therapeutics had 12 more articles in the media than Lisata Therapeutics. MarketBeat recorded 13 mentions for Polaryx Therapeutics and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Polaryx Therapeutics' score of 0.87 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Positive
Lisata Therapeutics	Very Positive

Polaryx Therapeutics has higher earnings, but lower revenue than Lisata Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.86	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Lisata Therapeutics	N/A	-103.54%	-83.08%

8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Polaryx Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 264.81%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 358.72%. Given Lisata Therapeutics' higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Polaryx Therapeutics and Lisata Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Lisata Therapeutics' return on equity of -103.54% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 358.72%. Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 741.58%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cardiol Therapeutics had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Cardiol Therapeutics' score of 1.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Very Positive
Cardiol Therapeutics	Positive

Lisata Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Lisata Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.86	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Summary

Lisata Therapeutics beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 1.5% of Promis Neurosciences shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Promis Neurosciences had 3 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Promis Neurosciences and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Promis Neurosciences' score of 0.97 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Promis Neurosciences	Positive
Lisata Therapeutics	Very Positive

Promis Neurosciences currently has a consensus price target of $24.00, suggesting a potential upside of 68.42%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 358.72%. Given Lisata Therapeutics' higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lisata Therapeutics has higher revenue and earnings than Promis Neurosciences. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.86	N/A

Promis Neurosciences has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Summary

Lisata Therapeutics beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lisata Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 358.72%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lisata Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	5.62	-$26.60M	-$5.58	N/A
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.86	N/A

Cue Biopharma has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, Cue Biopharma had 5 more articles in the media than Lisata Therapeutics. MarketBeat recorded 6 mentions for Cue Biopharma and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat Cue Biopharma's score of 0.74 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Positive
Lisata Therapeutics	Very Positive

Summary

Lisata Therapeutics beats Cue Biopharma on 8 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to enGene?

enGene (NASDAQ:ENGN) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

enGene's return on equity of -56.06% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Lisata Therapeutics	N/A	-103.54%	-83.08%

enGene has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

enGene presently has a consensus price target of $11.05, indicating a potential upside of 481.34%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 358.72%. Given enGene's stronger consensus rating and higher possible upside, equities research analysts clearly believe enGene is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, enGene had 8 more articles in the media than Lisata Therapeutics. MarketBeat recorded 9 mentions for enGene and 1 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.87 beat enGene's score of 0.44 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Lisata Therapeutics	Very Positive

64.2% of enGene shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 10.5% of enGene shares are held by company insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lisata Therapeutics has higher revenue and earnings than enGene. Lisata Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.86	N/A

Summary

enGene beats Lisata Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.78M	$3.71B	$7.08B	$12.66B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-1.76	11.61	22.67	22.18
Price / Sales	175.23	223.15	501.23	86.51
Price / Cash	N/A	61.98	29.24	49.38
Price / Book	1.97	8.70	10.98	6.43
Net Income	-$16.59M	$23.83M	$3.59B	$331.16M
7 Day Performance	-1.80%	-0.75%	-0.26%	0.35%
1 Month Performance	-8.15%	8.68%	4.55%	0.57%
1 Year Performance	20.66%	55.85%	29.86%	22.26%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	1.9329 of 5 stars	$3.27 +1.2%	$15.00 +358.7%	+20.7%	$29.78M	$170K	N/A	30	Positive News Gap Up High Trading Volume
PLYX Polaryx Therapeutics	3.5318 of 5 stars	$2.58 -3.0%	$10.00 +287.6%	N/A	$121.34M	N/A	N/A	11	Trending News Analyst Forecast Analyst Revision
CRDL Cardiol Therapeutics	2.0517 of 5 stars	$1.05 -0.9%	$8.50 +709.5%	-21.7%	$121.01M	N/A	N/A	20	News Coverage
PMN Promis Neurosciences	4.1059 of 5 stars	$13.45 +2.2%	$26.50 +97.0%	+46.0%	$120.62M	N/A	N/A	5	News Coverage Analyst Upgrade Gap Down
CUE Cue Biopharma	0.3047 of 5 stars	$28.34 -10.2%	N/A	-94.7%	$119.03M	$27.47M	N/A	60	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. PLYX, CRDL, PMN, CUE, and ENGN

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Summary

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Summary

How does Lisata Therapeutics compare to Promis Neurosciences?

Summary

How does Lisata Therapeutics compare to Cue Biopharma?

Summary

How does Lisata Therapeutics compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. PLYX, CRDL, PMN, CUE, and ENGN

How does Lisata Therapeutics compare to Polaryx Therapeutics?

Does the media refer more to PLYX or LSTA?

Which has preferable valuation & earnings, PLYX or LSTA?

Is PLYX or LSTA more profitable?

Do insiders & institutionals believe in PLYX or LSTA?

Do analysts rate PLYX or LSTA?

Summary

How does Lisata Therapeutics compare to Cardiol Therapeutics?

Is LSTA or CRDL more profitable?

Do analysts recommend LSTA or CRDL?

Do institutionals & insiders believe in LSTA or CRDL?

Does the media favor LSTA or CRDL?

Which has more risk and volatility, LSTA or CRDL?

Which has better earnings & valuation, LSTA or CRDL?

Summary

How does Lisata Therapeutics compare to Promis Neurosciences?

Do institutionals and insiders believe in PMN or LSTA?

Does the media prefer PMN or LSTA?

Do analysts prefer PMN or LSTA?

Which has higher earnings and valuation, PMN or LSTA?

Which has more volatility & risk, PMN or LSTA?

Is PMN or LSTA more profitable?

Summary

How does Lisata Therapeutics compare to Cue Biopharma?

Do insiders and institutionals believe in CUE or LSTA?

Is CUE or LSTA more profitable?

Do analysts prefer CUE or LSTA?

Which has preferable earnings & valuation, CUE or LSTA?

Which has more volatility and risk, CUE or LSTA?

Does the media favor CUE or LSTA?

Summary

How does Lisata Therapeutics compare to enGene?

Is ENGN or LSTA more profitable?

Which has more risk & volatility, ENGN or LSTA?

Do analysts rate ENGN or LSTA?

Does the media refer more to ENGN or LSTA?

Do institutionals & insiders believe in ENGN or LSTA?

Which has higher valuation & earnings, ENGN or LSTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools